^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    STK11 mutation + KEAP1 mutation

    i
    Other names: Serine/Threonine-Protein Kinase 11, Liver Kinase B1, Serine/Threonine-Protein Kinase LKB1, Polarization-Related Protein LKB1, STK11, Serine/Threonine Kinase 11, Serine/Threonine-Protein Kinase STK11, Renal Carcinoma Antigen NY-REN-19, KEAP1, Kelch Like ECH Associated Protein 1, Cytosolic Inhibitor Of Nrf2, Kelch-Like Family Member 19, Kelch-Like Protein 19, KLHL19, INrf2, KEAP1 Delta C, KIAA0132, INRF2
    Entrez ID:
    6794; 9817
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    10ms
    Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial. (PubMed, Ann Oncol)
    ML-based immune phenotyping by spatial distribution of T cells in resected NSCLC is able to identify patients at greater risk of disease recurrence after surgical resection. LUADs with concurrent KEAP1 and STK11 mutations are enriched for altered and desert immune phenotypes.
    Retrospective data • Journal • Machine learning
    |
    STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1) • CD8 (cluster of differentiation 8)
    |
    STK11 mutation • KEAP1 mutation • STK11 mutation + KEAP1 mutation
    2years
    Genomic correlates of Metastasis in KRAS mutant lung adenocarcinoma (AACR 2022)
    While both KEAP1 and STK11 mutations are associated with decreased OS in KRAS-mutant LUAD, we find in two independent cohorts that only KEAP1 mutations and KEAP1/STK11 co-mutations, but not STK11 mutations, are associated with metastasis. We also found that FGA, TMB, CDKN2A/B deletions are strongly associated with metastasis. Further research is necessary to understand the influence of KEAP1 mutations, independent of and in-conjunction with STK11 mutations, on metastasis.
    Tumor mutational burden
    |
    KRAS (KRAS proto-oncogene GTPase) • TMB (Tumor Mutational Burden) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • KEAP1 (Kelch Like ECH Associated Protein 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • NFKBIA (NFKB Inhibitor Alpha 2)
    |
    KRAS mutation • STK11 mutation • CDKN2A deletion • KEAP1 mutation • STK11 mutation + KEAP1 mutation
    |
    MSK-IMPACT • OncoPanel™ Assay
    over3years
    [VIRTUAL] Analysis of Immune Microenvironment and Prognosis of NSCLC Patients Harbored SMARCA4 Mutation (IASLC-WCLC 2020)
    In POPLAR and OAK trials, we further made the similar result (P = 0.143) and SMARCA4 mutated patients who receiving chemotherapy had worse survival (P =0.016). In addition, we found that SMARCA4 mutated patients could benefit from immunotherapy with more than 4 months median survival extension compared with chemotherapy, Conclusion SMARCA4 mutated NSCLC patients had worse survival and could not benefit from chemotherapy as well as immunotherapy; however, survival of these patients receiving immunotherapy is better than that receiving chemotherapy
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • CD4 (CD4 Molecule)
    |
    STK11 mutation • KEAP1 mutation • SMARCA4 mutation • STK11 mutation + KEAP1 mutation
    |
    MSK-IMPACT